RNASEH2B and Aicardi-Goutieres syndrome: One study examined potential cytotoxicity effects in stem cells derived from AGS patients with biallelic pathogenic variants in either TREX1, RNASEH2B and IFIH1 variants, however, efficacy was not examined, precluding further insights into immune-modulatory therapy in AGS326.